Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment

References

• Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S–94S.
   PubMed Web of Science ®Google Scholar
• Junqueira DR, Zorzela LM, Perini E. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev. 2017;4:007557. [ CD].
   Google Scholar
• Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007;83(983):575–582.
   PubMed Web of Science ®Google Scholar
• Greinacher A. CLINICAL PRACTICE. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373(3):252–261.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017;15(11):2099–2114.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502–507.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71(2):247–251.
   PubMed Web of Science ®Google Scholar
• Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest. 2007;131(6):1644–1649.
   PubMed Web of Science ®Google Scholar
• Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710–2715.
   PubMed Web of Science ®Google Scholar
• Warkentin TEGA. Heparin-induced thrombocytopenia. CRC Press; 2012.
   Google Scholar
• Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703–1708.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard J-AI, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108(9):2937–2941.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:340S–380S.
   PubMed Web of Science ®Google Scholar
• Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997;56(1):12–16.
   PubMed Web of Science ®Google Scholar
• Cuker A, Arepally GM, Chong BH, et al., American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22): 3360–3392.
   PubMed Web of Science ®Google Scholar
• Files JC, Malpass TW, Yee EK, et al. Studies of human plate alpha-granule release in vivo. Blood. 1981;58(3):607–618.
   PubMed Web of Science ®Google Scholar
• Arepally GM, Cines DB. Pathogenesis of heparin-induced thrombocytopenia. In: Transl Res. 2020;225:131-140.
   Google Scholar
• Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68(1):95–96.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84(11):3691–3699.
   PubMed Web of Science ®Google Scholar
• Kasthuri RS, Glover SL, Jonas W, et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood. 2012;119(22):5285–5293.
   PubMed Web of Science ®Google Scholar
• Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355(8):809–817.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Farner B, Kroll H, et al., Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005;94(7): 132–135.
   PubMedGoogle Scholar
• Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286–1292.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135(7):502–506.
   PubMed Web of Science ®Google Scholar
• Watson H, Davidson S, Keeling D, et al., Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol. 2012;159(5): 528–540.
   PubMed Web of Science ®Google Scholar
• Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004;164(1):66–70.
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996;92(2):494–497.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Roberts RS, Hirsh J, et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005;127(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759–765.
   PubMed Web of Science ®Google Scholar
• Cuker A, Gimotty PA, Crowther MA, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160–4167.
   PubMed Web of Science ®Google Scholar
• Pishko AM, Fardin S, Lefler DS, et al. Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3155–3162.
   PubMed Web of Science ®Google Scholar
• Linkins L-A, Bates SM, Lee AYY, et al. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood. 2015;126(5):597–603.
   PubMed Web of Science ®Google Scholar
• Sun L, Gimotty PA, Lakshmanan S, et al. Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. A systematic review and meta-analysis. Thromb Haemost. 2016;115(5):1044–1055.
   PubMed Web of Science ®Google Scholar
• Nagler M, Lm B, Ten Cate H, et al. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2016;127(5):546–557.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Barelli S, Zermatten MG, et al. Rapid and accurate Bayesian diagnosis of heparin-induced thrombocytopenia. Blood. 2020;135(14):1171–1184.
   PubMed Web of Science ®Google Scholar
• Liederman Z, Van Cott EM, Smock K, et al., Heparin-induced thrombocytopenia: an international assessment of the quality of laboratory testing. J Thromb Haemost. 2019;17(12): 2123–2130.
   PubMed Web of Science ®Google Scholar
• Jang I-K, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005;111(20):2671–2683.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Mohammed S, Donikian D, et al. A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia. Pathology. 2021;53(2):247–256.
   PubMed Web of Science ®Google Scholar
• Cuker A. Management of the multiple phases of heparin-induced thrombocytopenia. Thromb Haemost. 2016;116(11):835–842.
   PubMedGoogle Scholar
• Farner B, Eichler P, Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001;85:950–957.
   PubMed Web of Science ®Google Scholar
• Hopkins CK, Goldfinger D Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion. 2008;48:2128–2132.
   Google Scholar
• Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103(14):1838–1843.
   PubMed Web of Science ®Google Scholar
• Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163(15):1849–1856.
   PubMed Web of Science ®Google Scholar
• Be L, De W, Mj H, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia [Internet]. Chest. cited 2020 Sep 29]. Available from 2006;; : https://pubmed.ncbi.nlm.nih.gov/16778256/
   Web of Science ®Google Scholar
• Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353(10):1028–1040.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15(11):611–616.
   PubMedGoogle Scholar
• Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007;83(2):572–577.
   PubMed Web of Science ®Google Scholar
• Joseph L, Casanegra AI, Dhariwal M, et al. Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia. J Thromb Haemost. 2014;12(7):1044–1053.
   PubMed Web of Science ®Google Scholar
• Sun Z, Lan X, Li S, et al. Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis. Int J Hematol. 2017;106(4):476–483.
   PubMed Web of Science ®Google Scholar
• Boyce SW, Bandyk DF, Bartholomew JR, et al. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study. Am J Ther. 2011;18(1):14–22.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circul. 1999;100:587–593.
   Google Scholar
• Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99(1):73–80.
   PubMed Web of Science ®Google Scholar
• Lubenow N, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005;3(11):2428–2436.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Withdrawal of the marketing authorisation in the European Union [Internet]. 2012. [cited 2020 Oct 1]. Available from: https://www.ema.europa.eu/en/documents/public-statement/public-statement-refludan-withdrawal-marketing-authorisation-european-union_en.pdf.
   Google Scholar
• Chong BH, Gallus AS, Cade JF, et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001;86(11):1170–1175.
   PubMedGoogle Scholar
• Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost. 2006;95(6):967–981.
   PubMed Web of Science ®Google Scholar
• Linkins L-A, Hu G, Warkentin TE. Systematic review of fondaparinux for heparin-induced thrombocytopenia: when there are no randomized controlled trials. Res Pract Thromb Haemost. 2018;2(4):678–683.
   PubMed Web of Science ®Google Scholar
• Pistulli R, Oberle V, Figulla H-R, et al. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia. Blood Coagul Fibrinolysis. 2011;22(1):76–78.
   PubMed Web of Science ®Google Scholar
• Linkins L-A, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic Therapy and Prevention of Thrombosis. In: Chest. Vol. 141, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines; 2012;141(2 Suppl):e495S–e530S.
   Google Scholar
• Huisman MV, Rothman KJ, Paquette M, et al. The Changing Landscape for Stroke Prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69:777–785.
   PubMed Web of Science ®Google Scholar
• Barlow A, Barlow B, Reinaker T, et al. Potential Role of Direct Oral Anticoagulants in the Management of Heparin-induced Thrombocytopenia. Pharmacotherapy. 2019;39(8):837–853.
   PubMed Web of Science ®Google Scholar
• Linkins LA, Warkentin TE, Pai M, et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost. 2016;14(6):1206–1210.
   PubMed Web of Science ®Google Scholar
• Farasatinasab M, Zarei B, Moghtadaei M, et al. Rivaroxaban as an Alternative Agent for Heparin-Induced Thrombocytopenia. J Clin Pharmacol. 2020;60(10):1362–1366.
   PubMed Web of Science ®Google Scholar
• Nasiripour S, Saif M, Farasatinasab M, et al. Dabigatran as a Treatment Option for Heparin-Induced Thrombocytopenia. J Clin Pharmacol. 2019;59(1):107–111.
   PubMed Web of Science ®Google Scholar
• Di Pilla M, Barco S, Sacco C, et al. Acute limb ischemia in a patient with pre-fibrotic myelofibrosis complicated by heparin-induced thrombocytopenia and thrombosis - case report and systematic review of dabigatran use. VASA Zeitschrift fur Gefasskrankheiten. 2020;1–6.
   Google Scholar
• Manji F, Warkentin TE, Sheppard J-AI, et al. Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban. Platelets. 2020;31(1):124–127.
   PubMed Web of Science ®Google Scholar
• Samoš M, Bolek T, Škorňová I, et al. Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement? J Thromb Thrombolysis. 2019;48(4):619–622.
   PubMed Web of Science ®Google Scholar
• Bienz MJ, Obrocki P, Russell J, et al. Heparin-induced thrombocytopaenia presenting as acute aortic mural thrombosis. BJR case reports. 2019;5(1):20180025.
   Google Scholar
• Huang H, Lin Y, Yao R-X, et al. Successful Treatment of Severe Heparin-induced Thrombocytopenia with Intravenous Immunoglobulin, Platelet Transfusion and Rivaroxaban: a Case Report. Chinese Medical Sciences Journal. 2019;34(1):60–64.
   Google Scholar
• Trujillo Agudelo D, Ramirez Quintero JD, Arango Barrientos M. Successful treatment of heparin-induced thrombocytopenia with apixaban in a patient with chronic kidney disease requiring hemodialysis. Clin Case Rep. 2018;6(11):2147–2149.
   PubMed Web of Science ®Google Scholar
• Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol. 2019;12(8):685–698.
   PubMed Web of Science ®Google Scholar
• Grau E, Linares M, Olaso MA, et al. Heparin-induced thrombocytopenia–response to intravenous immunoglobulin in vivo and in vitro. Am J Hematol. 1992;39(4):312–313.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Liebenhoff U, Kiefel V, et al. Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation–a possible new indication for high dose i.v. IgG. Thromb Haemost. 1994;71(5):641–645.
   PubMed Web of Science ®Google Scholar
• Padmanabhan A, Jones CG, Pechauer SM, et al. IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. Chest. 2017;152(3):478–485.
   PubMed Web of Science ®Google Scholar
• Tvito A, Bakchoul T, Rowe JM, et al. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. Am J Hematol. 2015;90(7):675–678.
   PubMed Web of Science ®Google Scholar
• Welsby IJ, Um J, Milano CA, et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg. 2010;110(1):30–35.
   PubMed Web of Science ®Google Scholar
• Onuoha C, Barton KD, Wong ECC, et al. Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin-induced thrombocytopenia: a systematic review. In Transfusion. 2020;60(11):2714-2736.
   Google Scholar
• Ni X, Castanares M, Mukherjee A, et al. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011;18(27):4206–4214.
   PubMed Web of Science ®Google Scholar
• Troisi R, Napolitano V, Spiridonova V, et al. Several structural motifs cooperate in determining the highly effective anti-thrombin activity of NU172 aptamer. Nucleic Acids Res. 2018;46(22):12177–12185.
   PubMed Web of Science ®Google Scholar
• Jaax ME, Krauel K, Marschall T, et al. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood. 2013;122(2):272–281.
   PubMed Web of Science ®Google Scholar
• Wakui K, Yoshitomi T, Yamaguchi A, et al. Rapidly Neutralizable and Highly Anticoagulant Thrombin-Binding DNA Aptamer Discovered by MACE SELEX. Mol Ther Nucleic Acids. 2019;16:348–359.
   PubMedGoogle Scholar
• Trapaidze A, J-p H, Herbert J-M, et al. Investigation of the selectivity of thrombin-binding aptamers for thrombin titration in murine plasma. Biosens Bioelectron. 2016;78:58–66.
   PubMed Web of Science ®Google Scholar
• Stoll H, Steinle H, Wilhelm N, et al. Rapid Complexation of Aptamers by Their Specific Antidotes. Molecules. 2017;22(6):22. Basel, Switzerland
   Web of Science ®Google Scholar
• Porro B, Songia P, Squellerio I, et al. Analysis, physiological and clinical significance of 12-HETE: a neglected platelet-derived 12-lipoxygenase product. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;964:26–40.
   PubMed Web of Science ®Google Scholar
• Yeung J, Tourdot BE, Fernandez-Perez P, et al. Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation. Blood. 2014;124(14):2271–2279.
   PubMed Web of Science ®Google Scholar
• Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72(3):925–930.
   PubMed Web of Science ®Google Scholar
• Adili R, Tourdot BE, Mast K, et al. First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis. Arterioscler Thromb Vasc Biol. 2017;37(10):1828–1839.
   PubMed Web of Science ®Google Scholar
• McMahon CM, Cuker A. The 4Ts test in the critically ill: timing is everything. J Crit Care. 2014;29(3):468–469.
   PubMed Web of Science ®Google Scholar
• Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8(12):2642–2650.
   PubMed Web of Science ®Google Scholar
• Lillo-Le Louët A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost. 2004;2(11):1882–1888.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, McCaughan G, Mohammed S, et al. HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia. Pathology. 2018;50(4):426–436.
   PubMed Web of Science ®Google Scholar
• Kang M, Alahmadi M, Sawh S, et al., Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015;125(6): 924–929.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Makris M, Jay RM, et al. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med. 2008;121(7):632–636.
   PubMed Web of Science ®Google Scholar
• Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of “spontaneous” HIT? J Thromb Haemost. 2008;6(9):1598–1600.
   PubMed Web of Science ®Google Scholar
• Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2012;12(10):1299–1313.
   PubMed Web of Science ®Google Scholar